Morgan Stanley
GMAB icon

Morgan Stanley’s Genmab GMAB Stock Holding History

Morgan Stanley’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.6M Buy
2,184,701
+350,262
+19% +$10.5M ﹤0.01% 1930
2025
Q4 		$56.5M Buy
1,834,439
+159,865
+10% +$4.98M ﹤0.01% 1964
2025
Q3 		$51.4M Sell
1,674,574
-1,022,561
-38% -$24.9M ﹤0.01% 1985
2025
Q2 		$55.7M Sell
2,697,135
-141,793
-5% -$2.91M ﹤0.01% 1817
2025
Q1 		$55.6M Buy
2,838,928
+33,047
+1% +$693K ﹤0.01% 1717
2024
Q4 		$58.6M Buy
2,805,881
+1,165,491
+71% +$25.6M ﹤0.01% 1697
2024
Q3 		$40M Buy
1,640,390
+611,013
+59% +$16.3M ﹤0.01% 2066
2024
Q2 		$25.9M Buy
1,029,377
+55,341
+6% +$1.57M ﹤0.01% 2389
2024
Q1 		$29.1M Sell
974,036
-1,204,158
-55% -$35.4M ﹤0.01% 2280
2023
Q4 		$69.4M Buy
2,178,194
+1,077,675
+98% +$33.8M ﹤0.01% 2103
2023
Q3 		$38.8M Buy
1,100,519
+91,639
+9% +$3.49M ﹤0.01% 1813
2023
Q2 		$38.3M Sell
1,008,880
-67,712
-6% -$2.7M ﹤0.01% 1844
2023
Q1 		$40.7M Sell
1,076,592
-139,269
-11% -$5.35M ﹤0.01% 1739
2022
Q4 		$51.5M Buy
1,215,861
+347,824
+40% +$14.3M 0.01% 1476
2022
Q3 		$27.9M Buy
868,037
+139,532
+19% +$4.9M ﹤0.01% 1848
2022
Q2 		$23.7M Buy
728,505
+622,902
+590% +$20.2M ﹤0.01% 2099
2022
Q1 		$3.82M Sell
105,603
-37,231
-26% -$1.28M ﹤0.01% 3968
2021
Q4 		$5.65M Sell
142,834
-33,650
-19% -$1.4M ﹤0.01% 3591
2021
Q3 		$7.71M Sell
176,484
-66,012
-27% -$2.96M ﹤0.01% 3218
2021
Q2 		$9.9M Sell
242,496
-123,627
-34% -$4.77M ﹤0.01% 2994
2021
Q1 		$12M Sell
366,123
-170,119
-32% -$6.4M ﹤0.01% 2463
2020
Q4 		$21.8M Sell
536,242
-324,339
-38% -$12.1M ﹤0.01% 1728
2020
Q3 		$31.5M Sell
860,581
-420,700
-33% -$15.2M 0.01% 1161
2020
Q2 		$43.4M Buy
1,281,281
+1,059,913
+479% +$28.9M 0.01% 909
2020
Q1 		$4.69M Buy
221,368
+42,804
+24% +$954K ﹤0.01% 2517
2019
Q4 		$3.99M Buy
178,564
+68,767
+63% +$1.5M ﹤0.01% 3439
2019
Q3 		$2.22M Buy
+109,797
New +$2.16M ﹤0.01% 3684

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Morgan Stanley's GMAB Position: Q1 2026 in Review

Morgan Stanley increased its Genmab (GMAB) stake by 19% in Q1 2026, buying an estimated $10.5M and bringing the position to 2,184,701 shares worth $58.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1930.

Morgan Stanley first reported a position in GMAB in Q3 2019 and has held it in 27 quarters since. The position peaked at $69.4M in Q4 2023. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Morgan Stanley held 2,184,701 shares of Genmab worth $58.6M as of Q1 2026.
  • Morgan Stanley bought 350,262 Genmab shares in Q1 2026, an estimated $10.5M.
  • Genmab made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #1930 holding.
  • Morgan Stanley first reported a position in Genmab in Q3 2019 and has held it in 27 quarters since.
  • Morgan Stanley's Genmab position peaked at $69.4M in Q4 2023.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.